Overview:  Master the most frequently asked Golang interview questions covering language fundamentals, concurrency, interfaces, error handling, and modern ...

In 2014, the first flood caught the sleeping residents of the Javanese village off guard. Since then, rising sea tides have kept engulfing the village. The water is still rising — up to 15 centimeters ...

YouTube is full of information on almost any topic, and the same applies to electronics. Over the years, many YouTube channels have emerged that provide engineers with how-to info on design techniques ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

Angela Rasmussen, a world-renowned virologist at the University of Saskatchewan, endured a lot of body-shaming when she spoke publicly during the pandemic. She talks with CBC’s Leisha Grebinski about ...

Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in ...

April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic made by Indian drugmaker Dr ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.